Ligand Pharmaceuticals Inc (LGND) stock
LGNDNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as LGNDZ, LGNXZ, LGNYZ, LGNZZ
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 6/30455% above fair value
$298.71+4.90 (+1.67%)
Close on Nov 18, 2026Market cap $5.98BP/E 130.4Yield –
Ligand Pharmaceuticals cash
Cash and short-term investments held at the end of each period.
Ligand Pharmaceuticals's cash was $447.40M at Sep 30, 2026. For fiscal 2025 it was $733.52M, up 186.3% from the year before. Over ten years it grew 13.9% a year on average. The highest annual figure on record is $1.07B in fiscal 2019.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $733.52M | +186.3% |
| FY2024 | Dec 31, 2024 | $256.17M | +50.4% |
| FY2023 | Dec 31, 2023 | $170.31M | -19.6% |
| FY2022 | Dec 31, 2022 | $211.87M | -37.9% |
| FY2021 | Dec 31, 2021 | $341.11M | -17.1% |
| FY2020 | Dec 31, 2020 | $411.53M | -61.6% |
| FY2019 | Dec 31, 2019 | $1.07B | +48.5% |
| FY2018 | Dec 31, 2018 | $721.00M | +257.5% |
| FY2017 | Dec 31, 2017 | $201.66M | +43.0% |
| FY2016 | Dec 31, 2016 | $141.05M | -29.6% |
| FY2015 | Dec 31, 2015 | $200.22M | +19.7% |
| FY2014 | Dec 31, 2014 | $167.34M | +947.2% |
| FY2013 | Dec 31, 2013 | $15.98M | +29.1% |
| FY2012 | Dec 31, 2012 | $12.38M | -27.3% |
| FY2011 | Dec 31, 2011 | $17.04M | -24.9% |
| FY2010 | Dec 31, 2010 | $22.70M | +41.6% |
| FY2009 | Dec 31, 2009 | $16.03M | -44.2% |
| FY2008 | Dec 31, 2008 | $28.75M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $447.40M | -32.7% |
| Q2 FY2026 | Jun 30, 2026 | $1.36B | +454.1% |
| Q1 FY2026 | Mar 31, 2026 | $779.41M | +273.1% |
| Q4 FY2025 | Dec 31, 2025 | $733.52M | +186.3% |
| Q3 FY2025 | Sep 30, 2025 | $664.52M | +202.5% |
| Q2 FY2025 | Jun 30, 2025 | $245.02M | +8.0% |
| Q1 FY2025 | Mar 31, 2025 | $208.90M | -32.7% |
| Q4 FY2024 | Dec 31, 2024 | $256.17M | +50.4% |
| Q3 FY2024 | Sep 30, 2024 | $219.64M | +14.9% |
| Q2 FY2024 | Jun 30, 2024 | $226.93M | +3.6% |
| Q1 FY2024 | Mar 31, 2024 | $310.59M | +9.9% |
| Q4 FY2023 | Dec 31, 2023 | $170.31M | -19.6% |
| Q3 FY2023 | Sep 30, 2023 | $191.09M | +57.4% |
| Q2 FY2023 | Jun 30, 2023 | $219.04M | +48.1% |
| Q1 FY2023 | Mar 31, 2023 | $282.67M | +38.6% |
| Q4 FY2022 | Dec 31, 2022 | $211.87M | -37.9% |
| Q3 FY2022 | Sep 30, 2022 | $121.41M | -62.4% |
| Q2 FY2022 | Jun 30, 2022 | $147.94M | -51.0% |
| Q1 FY2022 | Mar 31, 2022 | $204.00M | -39.9% |
| Q4 FY2021 | Dec 31, 2021 | $341.11M | -17.1% |
| Q3 FY2021 | Sep 30, 2021 | $323.21M | -59.4% |
| Q2 FY2021 | Jun 30, 2021 | $301.98M | -62.7% |
| Q1 FY2021 | Mar 31, 2021 | $339.55M | -54.1% |
| Q4 FY2020 | Dec 31, 2020 | $411.53M | -61.6% |
| Q3 FY2020 | Sep 30, 2020 | $795.26M | -27.7% |
| Q2 FY2020 | Jun 30, 2020 | $810.61M | -39.2% |
| Q1 FY2020 | Mar 31, 2020 | $739.54M | -48.3% |
| Q4 FY2019 | Dec 31, 2019 | $1.07B | +48.5% |
| Q3 FY2019 | Sep 30, 2019 | $1.10B | +4.8% |
| Q2 FY2019 | Jun 30, 2019 | $1.33B | +39.3% |
| Q1 FY2019 | Mar 31, 2019 | $1.43B | +441.3% |
| Q4 FY2018 | Dec 31, 2018 | $721.00M | +257.5% |
| Q3 FY2018 | Sep 30, 2018 | $1.05B | +419.3% |
| Q2 FY2018 | Jun 30, 2018 | $956.93M | +454.3% |
| Q1 FY2018 | Mar 31, 2018 | $264.35M | +65.9% |
| Q4 FY2017 | Dec 31, 2017 | $201.66M | +43.0% |
| Q3 FY2017 | Sep 30, 2017 | $202.26M | – |
| Q2 FY2017 | Jun 30, 2017 | $172.63M | – |
| Q1 FY2017 | Mar 31, 2017 | $159.37M | – |
| Q4 FY2016 | Dec 31, 2016 | $141.05M | – |
See a number that looks wrong?